

Neuroimaging

Untangling tau imaging

Victor L. Villemagne^{a,b,c,*}, Nobuyuki Okamura^d, Christopher C. Rowe^{a,c}

^aDepartment of Molecular Imaging & Therapy, Centre for PET, Austin Health, Melbourne, Australia

^bThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Australia

^cDepartment of Medicine, The University of Melbourne, Melbourne, Australia

^dDepartment of Pharmacology, Tohoku University, Sendai, Japan


Abstract

In vivo imaging of tau deposits is providing a better understanding of the temporal and spatial tau deposition in the brain, allowing a more comprehensive insight into the causes, diagnoses, and potentially treatment of tauopathies such as Alzheimer's disease, progressive supranuclear palsy, corticobasal syndrome, chronic traumatic encephalopathy, and some variants of frontotemporal lobar degeneration. The assessment of tau deposition in the brain over time will allow a deeper understanding of the relationship between tau and other variables such as cognition, genotype, and neurodegeneration, as well as assessing the role tau plays in ageing. Preliminary human studies suggest that tau imaging could also be used as a diagnostic, prognostic, and theranostic biomarker, as well as a surrogate marker for target engagement, patient recruitment, and efficacy monitoring for disease-specific therapeutic trials.

© 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Keywords:

PET; Tau imaging; Alzheimer's disease; Positron emission tomography; Tauopathies; Dementia



Acknowledgments

We thank Professors Yukitsuda Kudo, Colin Masters, Kazuhiko Yanai, Shozo Furumoto, Drs Ryuichi Harada, Michelle Fodero-Tavoletti, William P. Blatty, Mrs Svetlana Pejoska-Bozinovski, Ms Fiona Lamb, and the Brain Research Institute for their assistance with this study. This review was supported in part by NHMRC Project Grant 1044361. VLV is supported by NHMRC Research Fellowship 1046471. The funding sources had no input into the design of this study, the analysis of data, or writing of the manuscript.

V.L.V. has received speaker honoraria from GE Healthcare, Piramal Imaging, and Avid Radiopharmaceuticals and consulting honoraria from Novartis and Lundbeck. N.O. has received research support from Clino Co. Ltd. THK compounds have been licensed to GE Healthcare. C.C.R. has received speaker honoraria from received speaker and consulting honoraria

from GE Healthcare, Piramal Imaging, Avid Radiopharmaceuticals, Navidea, and AstraZeneca.

*Corresponding author. Tel.: +61-394963321; Fax: +61-3-9496 5663. E-mail address: victorlv@unimelb.edu.au

<http://dx.doi.org/10.1016/j.dadm.2016.05.001>

2352-8729/© 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Supplementary data

Supplementary data related to this article can be found at <http://dx.doi.org/10.1016/j.dadm.2016.05.001>.

Reference mentioned in this video article can be found here.

References

- [1] Chen-Plotkin AS, Lee VM, Trojanowski JQ. TAR DNA-binding protein 43 in neurodegenerative disease. *Nat Rev Neurol* 2010; 6:211–20.
- [2] Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. *CNS Drugs* 2010;24:375–98.
- [3] Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, van Swieten JC. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. *J Neurol Neurosurg Psychiatry* 2011;82:476–86.
- [4] Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. *Ann Neurol* 2004;55:306–19.
- [5] Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. *Lancet Neurol* 2008;7:129–35.
- [6] Rowe CC, Pejoska S, Mulligan RS, Jones G, Chan JG, Svensson S, et al. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia. *J Nucl Med* 2013;54:880–6.
- [7] Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. *Ann Neurol* 2010;68:319–29.
- [8] Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). *J Nucl Med* 2010;51:913–20.
- [9] Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. *Brain Res Brain Res Rev* 2000;33:95–130.
- [10] Maas T, Eidenmuller J, Brandt R. Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments. *J Biol Chem* 2000;275:15733–40.
- [11] Li X, Kumar Y, Zempel H, Mandelkow EM, Biernat J, Mandelkow E. Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration. *EMBO J* 2011;30:4825–37.
- [12] Hernandez F, Avila J. Tauopathies. *Cell Mol Life Sci* 2007; 64:2219–33.
- [13] Arima K. Ultrastructural characteristics of tau filaments in tauopathies: immuno-electron microscopic demonstration of tau filaments in tauopathies. *Neuropathology* 2006;26:475–83.
- [14] Zempel H, Luedtke J, Kumar Y, Biernat J, Dawson H, Mandelkow E, et al. Amyloid-beta oligomers induce synaptic damage via Tau-dependent microtubule severing by TTL6 and spastin. *EMBO J* 2013;32:2920–37.
- [15] Zempel H, Thies E, Mandelkow E, Mandelkow EM. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. *J Neurosci* 2010;30:11938–50.
- [16] Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. *J Neural Transm Suppl* 1998;53:127–40.
- [17] Delacourte A, David JP, Sergeant N, Buee L, Watzet A, Vermersch P, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. *Neurology* 1999;52:1158–65.
- [18] Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. *Neurobiol Aging* 1997;18:351–7.
- [19] Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological Alterations in Alzheimer Disease. *Cold Spring Harb Perspect Med* 2011;1:a006189.
- [20] Guo JL, Lee VM. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. *J Biol Chem* 2011;286:15317–31.
- [21] Mohorko N, Bresjanac M. Tau Protein And Human Tauopathies: An Overview. *Zdrav Vestn* 2008;77:35–41.
- [22] Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. *Annu Rev Neurosci* 2001;24:1121–59.
- [23] McKee AC, Cantu RC, Nowinski CJ, Hedley-Whyte ET, Gavett BE, Budson AE, et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. *J Neuropathol Exp Neurol* 2009;68:709–35.
- [24] Masters CL, Selkoe DJ. Biochemistry of amyloid beta-protein and amyloid deposits in Alzheimer disease. *Cold Spring Harb Perspect Med* 2012;2:a006262.
- [25] Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. *Neurology* 1992;42:631–9.
- [26] Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. *Neurology* 2007; 68:1718–25.
- [27] McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. *Ann Neurol* 1999;46:860–6.
- [28] Zempel H, Mandelkow EM. Linking amyloid-beta and tau: amyloid-beta induced synaptic dysfunction via local wreckage of the neuronal cytoskeleton. *Neurodegener Dis* 2012;10:64–72.
- [29] Ittner LM, Ke YD, Gotz J. Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease. *J Biol Chem* 2009;284:20909–16.
- [30] Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. *Ann Neurol* 1999;45:358–68.
- [31] Villemagne VL, Fodero-Tavoletti MT, Pike KE, Cappai R, Masters CL, Rowe CC. The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer's Disease and other Dementias. *Mol Neurobiol* 2008;38:1–15.
- [32] Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *Lancet Neurol* 2013;12:207–16.
- [33] Jack CR Jr, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. *Ann Neurol* 2012;71:765–75.
- [34] Dutra JR, Cortes EP, Vonsattel JP. Update on Hippocampal Sclerosis. *Curr Neurol Neurosci Rep* 2015;15:592.
- [35] Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. *Acta Neuropathol* 2014; 128:755–66.
- [36] Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Harada R, Mulligan RS, Kudo T, et al. The Challenges of Tau Imaging. *Future Neurol* 2012;7:409–21.
- [37] Villemagne VL, Okamura N. In vivo tau imaging: Obstacles and progress. *Alzheimers Dement* 2014;10:S254–64.
- [38] Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. *Lancet Neurol* 2015; 14:114–24.
- [39] Wegmann S, Jung YJ, Chinnathambi S, Mandelkow EM, Mandelkow E, Muller DJ. Human Tau isoforms assemble into ribbon-like fibrils that display polymorphic structure and stability. *J Biol Chem* 2010;285:27302–13.

Download English Version:

<https://daneshyari.com/en/article/3031972>

Download Persian Version:

<https://daneshyari.com/article/3031972>

[Daneshyari.com](https://daneshyari.com)